Previous studies in the rat have demonstrated that 11-deoxycortisol [compound S (pregn-4-ene-17α,21-diol-3,20-dione)], a competitive glucocorticoid antagonist in vitro, fails to behave as an antagonist in growth and adrenal suppression bioassays in nonadrenalectomized animals. This is probably explained by conversion of 11-deoxycortisol to cortisol by the adrenal glands. Δ1,9(11)-ll-Deoxycortisol (pregn-l,4,9(11)-triene-17α,21-diol-3,20 dione) has been shown to resist 11-hydroxylation because of the double bond at the 9–11 position and, hence, should be a more effective antiglucocorticoid in vivo. This hypothesis was tested by comparing the in vivo antiglucocorticoid activity of Δ1,9(11)-11-deoxycortisol with that of 11-deoxycortisol. The affinity of both compounds for the rat thymus glucocorticoid receptor was similar (equilibrium dissociation constant, 3 × 10-7 M). Both compounds antagonized dexamethasone-induced liver glycogen accumulation in nonadrenalectomized rats, Δ1,9(11)-11-deoxycortisol being 3-fold more potent than 11-deoxycortisol. Neither compound showed agonist activity in this bioassay. Δ1,9(11)-9(11)-11-Deoxycortisol showed partial agonist-antagonist activity in 1-week growth suppression and thymus suppression assays, while 11-deoxycortisol behaved as a glucocorticoid agonist. Both compounds failed to antagonize dexamethasone and acted as agonists of equal potency in a 1-week adrenal suppression assay. Δ1,9(11)-11-Deoxycortisol, administered to adrenalectomized rats, lost all its agonist activity in the growth suppression assay and exhibited only antagonist activity. These observations suggest that adrenal 11-hydroxylation of both 11-deoxycortisol and Δ1,9(11)-11-deoxycortisol produces metabolites with agonist activity. Δ1,9(11)-ll-Deoxycortisol retains antagonist activity, probably because conversion to the agonist metabolite is less complete and its intrinsic antagonist activity is greater. These observations support the hypothesis that analogs of 11-deoxycortisol with increased resistance to 11-hydroxylation will have increased antiglucocorticoid activity in intact (nonadrenalectomized) animals.
Background The World Health Organization named the phenomenon of misinformation spread through social media as an “infodemic” and recognized the need to curb it. Misinformation infodemics undermine not only population safety but also compliance to the suggestions and prophylactic measures recommended during pandemics. Objective The aim of this pilot study is to review the impact of social media on general population fear in “infoveillance” studies during the COVID-19 pandemic. Methods The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) protocol was followed, and 6 out of 20 studies were retrieved, meta-analyzed, and had their findings presented in the form of a forest plot. Results The summary random and significant event rate was 0.298 (95% CI 0.213-0.400), suggesting that social media–circulated misinformation related to COVID-19 triggered public fear and other psychological manifestations. These findings merit special attention by public health authorities. Conclusions Infodemiology and infoveillance are valid tools in the hands of epidemiologists to help prevent dissemination of false information, which has potentially damaging effects.
This chapter describes fear and its neuroendocrine regulation. It specifically highlights the role of elevated cortisol and corticotropin-releasing hormone (CRH) in the regulation of fear responses, placing a particular emphasis on the central nucleus of the amygdala and the bed nucleus of the stria terminalis. It starts with a discussion of the central motive state of fear and its biological basis. It then discusses the neural circuitry that underlies the perception of fearful events and fear-related behaviors. Next, it presents a description of the neuroendocrine basis of fear and a discussion of glucocorticoids and CRH in sustaining fear-related behaviors. Moreover, it evaluates the role of norepinephrine and epinephrine in facilitating responses to and memory of aversive events. It is showed that neuropeptides such as CRH chemically code the sense of fear that is sustained by elevated cortisol and that may underlie the excessively shy, fearful child's hyperexcitable central state.
Derangements in corticotropin‐releasing hormone (CRH) through its type 1 receptor (CRHR1) have been identified in many pathologic conditions. Preclinical models of addiction find that small‐molecule antagonists of CRHR1 can limit induction, maintenance, and relapse to drugs of abuse. Neuropsychiatric clinical trials of CRHR1 antagonists have shown mixed efficacy; treatment of addictive disorders has not been established, but finding effective treatments for addictive disorders is critical. Establishing effectiveness for substance abuse treatment will require a different design approach than was used for depression and anxiety trials. Focusing on active versus passive outcome measures, such as resilience to external stressful stimuli, may provide signals in curbing craving and relapse. Study design should include measures of abstinence and drug exposure, but additional elements of stress prevention should also be incorporated. Agents that could provide preemptive protection from drug use and relapse are novel and untested. An understanding of the evolutionary significance of the stress system and preclinical models suggests that these agents may provide protection in this manner. Investigators designing future trials might refocus their understanding of addiction and treatment in this new direction.
Endocrine disorders represent a large component of the so-called "chronic non-communicable diseases", which are responsible for the lion share of morbidity and mortality in contemporary societies. As discussed in this retrospective collection of articles, solid evidence from diabetes mellitus, the exemplar of common chronic endocrine disorders, highlights profound inequity in all aspects of endocrine disorders' management and outcomes that should be considered and addressed at large.